Naproxen
- Generic Name
- Naproxen
- Brand Names
- Aleve, Aleve PM, Aleve-D, Anaprox, Naprelan, Naprosyn, Sallus, Sudafed Sinus & Pain, Treximet, Vimovo
- Drug Type
- Small Molecule
- Chemical Formula
- C14H14O3
- CAS Number
- 22204-53-1
- Unique Ingredient Identifier
- 57Y76R9ATQ
- Background
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
- Indication
Naproxen is indicated for the management of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendinitis, bursitis, acute gout, primary dysmenorrhea, and for the relief of mild to moderate pain. Further, it is first-line therapy for osteoarthritis, acute gouty arthritis, dysmenorrhea, and musculoskeletal inflammation and pain.
- Associated Conditions
- Acute Gouty Arthritis, Acute Migraine, Ankylosing Spondylitis (AS), Back pain, Bursitis, Extra-Articular Rheumatism, Fever, Flu caused by Influenza, Headache, Juvenile Idiopathic Arthritis (JIA), Menstrual Distress (Dysmenorrhea), Migraine, Muscle Spasms, Nasal Congestion, Osteoarthritis (OA), Pain, Post Traumatic Pain, Postoperative pain, Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Seasonal Allergic Rhinitis, Sinusitis, Tendinitis, Toothache, Articular inflammation
Effect of Over-the-counter Analgesics on Postoperative Pain
- Conditions
- Pain Management
- Interventions
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Zitelli & Brodland Skin Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT06948513
- Locations
- 🇺🇸
Zitelli & Brodland Skin Cancer Center, Clairton, Pennsylvania, United States
Multimodal Pain Management After Wide Awake Local Anesthesia No Tourniquet Orthopedic Hand Surgery: A Randomized Control Trial
- Conditions
- Pain Management
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- University of Puerto Rico
- Target Recruit Count
- 100
- Registration Number
- NCT06917118
- Locations
- 🇵🇷
Oncological Hospital, San Juan, Puerto Rico
Non Steroidal Anti-inflammatory Drugs in the Prevention of Bone Pain Flares After Palliative Radiotherapy
- Conditions
- Bone Pain FlareBone Metastasis
- Interventions
- First Posted Date
- 2025-03-31
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- American University of Beirut Medical Center
- Target Recruit Count
- 385
- Registration Number
- NCT06903585
- Locations
- 🇱🇧
American University of Beirut Medical Center, Beirut, Lebanon
NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain
- Conditions
- DysmenorrheaChronic Pelvic PainPelvic Pain
- Interventions
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Endeavor Health
- Target Recruit Count
- 600
- Registration Number
- NCT06861920
- Locations
- 🇺🇸
Endeavor Health, Evanston, Illinois, United States
Comparing Trypsin-Chymotrypsin and Naproxen Sodium for Post-endodontic Treatment Pain
- Conditions
- Effect of Drug
- Interventions
- Drug: Trypsin-Chymotrypsin
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Dow University of Health Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT06562816
- Locations
- 🇵🇰
Dow University of Health Sciences, Karachi, Sindh, Pakistan
A Study to Learn About Whether BAYH006689 Causes Skin Irritation When Applied as a Topical Gel in Healthy Participants
- Conditions
- Healthy VolunteersPain
- Interventions
- Drug: Placebo GelDrug: A solution of 0.9% SalineDrug: A solution of 0.2% SLS
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 40
- Registration Number
- NCT06511973
- Locations
- 🇺🇸
TKL Research, Inc., Fair Lawn, New Jersey, United States
Pain Control After Lumbar Spine Fusion
- Conditions
- Postoperative PainSpine FusionNSAID (Non-Steroidal Anti-Inflammatory Drug)
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Rothman Institute Orthopaedics
- Target Recruit Count
- 428
- Registration Number
- NCT06484192
- Locations
- 🇺🇸
Rothman Orthopaedic Institute, Philadelphia, Pennsylvania, United States
PK,PD and DDI of Epaminurad and Naproxen in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- JW Pharmaceutical
- Target Recruit Count
- 28
- Registration Number
- NCT06435442
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Learn About Whether BAY H006689 Causes an Allergic Reaction When Applied as a Topical Gel in Healthy Participants
- Conditions
- PainHealthy Volunteers
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 236
- Registration Number
- NCT06415019
- Locations
- 🇺🇸
TKL Research, Inc., Fair Lawn, New Jersey, United States
Valacyclovir Monotherapy in Pain Management of Acute Periapical Abscesses After Emergency Chamber Opening
- Conditions
- Acute Apical Abscess
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Dow University of Health Sciences
- Target Recruit Count
- 82
- Registration Number
- NCT06344195
- Locations
- 🇵🇰
Dr. Yumna Shaheen Ali, Karachi, Sindh, Pakistan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.